Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Depreciation & Amortization - Total (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Depreciation & Amortization - Total for 4 consecutive years, with $37529.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization - Total fell 12.33% to $37529.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $170359.0 through Dec 2025, up 4.94% year-over-year, with the annual reading at $170359.0 for FY2025, 4.94% up from the prior year.
  • Depreciation & Amortization - Total for Q4 2025 was $37529.0 at bioAffinity Technologies, down from $44599.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization - Total was $166284.0 in Q4 2023, with the low at $800.0 in Q3 2022.
  • Average Depreciation & Amortization - Total over 4 years is $42488.4, with a median of $40357.5 recorded in 2024.
  • The sharpest move saw Depreciation & Amortization - Total skyrocketed 5536.88% in 2023, then plummeted 74.26% in 2024.
  • Over 4 years, Depreciation & Amortization - Total stood at $7282.0 in 2022, then surged by 2183.49% to $166284.0 in 2023, then tumbled by 74.26% to $42806.0 in 2024, then dropped by 12.33% to $37529.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization - Total over the past three periods came in at $37529.0, $44599.0, and $44468.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.